Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALN-ANG3
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALN-ANG3 is an investigational small interfering RNA (siRNA) therapeutic designed to lower blood lipid levels by targeting and inhibiting the production of angiopoietin-like protein 3 (ANGPTL3), a liver-derived protein that regulates plasma lipid and lipoprotein metabolism. By silencing ANGPTL3 mRNA in hepatocytes, ALN-ANG3 aims to reduce triglycerides and cholesterol levels in the blood. The drug is administered subcutaneously and is currently being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and effects on lipid parameters in healthy volunteers. It is being developed collaboratively by Alnylam Pharmaceuticals and Regeneron Pharmaceuticals[1][2][4][7].
02
Targets
ANGPTL3 (Angiopoietin-like protein 3)
Beyond the preview
Go deeper on ALN-ANG3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALN-ANG3.